Get a deeper look
Vectra provides biological insights that inform your clinical decisions when you assess RA disease activity
Watch video
A heterogeneous disease such as RA needs a comprehensive assessment

RA is a chronic, inflammatory disease that requires regular measurement of disease activity to prevent progressive joint damage.1

Structural damage can continue even when symptoms appear under control.1,2

No single biomarker has been proven reliable for predicting radiographic progression.3,4

Watch video

Have a question?

Want to order Vectra?

Case studies

Review case studies of Vectra use in clinical practice View Case Studies

Single biomarkers, such as CRP and ESR, are incomplete measures of RA disease activity.5

CRP and ESR levels were low in the majority of 9,135 patients with active RA (CDAI >2.8) studied from the CORRONA registry.5


CDAI = clinical disease activity index; CORRONA = Consortium of Rheumatology Researchers of North America; CRP = C-reactive protein; ESR = erythrocyte sedimentation rate; RA = rheumatoid arthritis


* 1. Mease PJ. The potential roles for novel biomarkers in rheumatoid arthritis assessment. Clin Exp Rheumatol. 2011;29(3):567-574

* 2. Brown AK, Conaghan PG, Karim Z, et al. An explanation for the apparent dissociation between clinical remission and continued structural deterioration in rheumatoid arthritis. Arthritis Rheum. 2008;58(10):2958- 2967

* 3. Hambardzumyan K, Bolce R, Saevarsdottir S, et al. Pretreatment multi-biomarker disease activity score and radiographic progression in early RA: results from the SWEFOT trial [published online ahead of print May 8, 2014]. Ann Rheum Dis. doi:10.1136/annrheumdis-2013-204986.

* 4. Karsdal MA, Woodworth T, Henriksen K, et al. Biochemical markers of ongoing joint damage in rheumatoid arthritis – current and future applications, limitations and opportunities. Arthritis Res Ther. 2011;13(2):215.

* 5. Kay J, Morgacheva O, Messing SP, et al. Clinical disease activity and acute phase reactant levels are discordant among patients with active rheumatoid arthritis: acute phase reactant levels contribute separately to predicting outcome at one year. Arthritis Res Ther. 2014;16(1):R40.

Case studies

Review case studies of Vectra use in clinical practice View Case Studies